Introduction:
This quiz collection on placebo ethics and randomized controlled trial (RCT) ethics is tailored for M.Pharm students to deepen understanding of ethical principles that govern clinical research. It covers key concepts such as clinical equipoise, informed consent, appropriate use of placebos, risks of deception, vulnerable populations, trial design choices (placebo-controlled, add-on, non-inferiority), institutional review board responsibilities, and post-trial obligations. Each question is designed to test both knowledge and applied judgment in real-world scenarios frequently encountered in drug development and regulatory review. Use these MCQs to prepare for exams and to sharpen decision-making skills required for ethical conduct of clinical trials.
Q1. Which ethical principle most directly justifies random assignment of participants to different treatment arms in an RCT?
- Respect for persons
- Beneficence
- Justice
- Clinical equipoise
Correct Answer: Clinical equipoise
Q2. According to the Declaration of Helsinki, when is it ethically acceptable to use a placebo in a clinical trial?
- Whenever placebo increases statistical power
- When no proven effective intervention exists or when withholding treatment poses no additional risk of serious harm
- When investigators want to blind participants
- When sponsor funding requires a placebo arm
Correct Answer: When no proven effective intervention exists or when withholding treatment poses no additional risk of serious harm
Q3. What does “clinical equipoise” mean in the context of RCT ethics?
- Investigators must have no prior clinical experience
- A genuine uncertainty within the expert medical community about the comparative therapeutic merits of each arm
- Patients must be unaware they are in a trial
- All participants must receive the same intervention eventually
Correct Answer: A genuine uncertainty within the expert medical community about the comparative therapeutic merits of each arm
Q4. Which design is ethically preferred when an effective standard therapy exists but researchers want to evaluate an experimental drug?
- Placebo-controlled superiority trial replacing standard care
- Add-on or active-comparator design where experimental drug is given with standard therapy
- Historical-control trial without concurrent control
- Single-arm open-label trial
Correct Answer: Add-on or active-comparator design where experimental drug is given with standard therapy
Q5. Informed consent for a trial that uses placebo must include which specific information?
- A guarantee that the participant will receive active treatment later
- The certainty of benefit from participating
- Clear explanation that a placebo may be used and potential risks of receiving placebo
- Detailed statistical analysis plan
Correct Answer: Clear explanation that a placebo may be used and potential risks of receiving placebo
Q6. Which population is considered especially vulnerable in placebo-controlled trials and requires additional protections?
- Healthy adult volunteers
- Prenatal patients, children, cognitively impaired persons, and economically disadvantaged groups
- Individuals with minor transient illnesses
- Experienced clinical trial participants
Correct Answer: Prenatal patients, children, cognitively impaired persons, and economically disadvantaged groups
Q7. When is a sham surgical procedure ethically permissible as a control?
- Whenever blinding is desired regardless of risk
- Only when there is no less risky method to obtain the scientific knowledge and risks are minimized and justified
- When a device trial is funded by industry
- When the surgical procedure is inexpensive
Correct Answer: Only when there is no less risky method to obtain the scientific knowledge and risks are minimized and justified
Q8. What is the ethical obligation known as “rescue medication” in placebo-controlled trials?
- Providing placebo to all participants after the trial
- Allowing participants access to symptomatic or emergency treatment to prevent harm if their condition worsens
- Ensuring all participants have free transportation
- Offering financial compensation for adverse events
Correct Answer: Allowing participants access to symptomatic or emergency treatment to prevent harm if their condition worsens
Q9. Which scenario most likely violates ethical standards for placebo use?
- Using placebo when there is no existing proven therapy
- Using placebo instead of an effective therapy for a life-threatening condition without safeguards
- Using placebo as add-on to standard care
- Using placebo with full informed consent and monitoring
Correct Answer: Using placebo instead of an effective therapy for a life-threatening condition without safeguards
Q10. What is a primary ethical concern in non-inferiority trials compared with placebo-controlled trials?
- They always require fewer participants
- Choice of an appropriate active comparator and demonstrating assay sensitivity to detect differences
- They do not require informed consent
- They can never be blinded
Correct Answer: Choice of an appropriate active comparator and demonstrating assay sensitivity to detect differences
Q11. Which regulatory or oversight body has primary responsibility to assess the ethical acceptability of placebo use in a trial?
- Clinical operations department of the sponsor
- Institutional Review Board (IRB) / Ethics Committee
- Marketing department
- Journal editorial board
Correct Answer: Institutional Review Board (IRB) / Ethics Committee
Q12. Deception in a clinical trial (not disclosing key study elements) is ethically problematic because:
- It always improves recruitment
- It undermines informed consent and respect for persons unless justified and debriefed
- It is required for all placebo trials
- It reduces administrative burden
Correct Answer: It undermines informed consent and respect for persons unless justified and debriefed
Q13. Which practice helps protect participants in placebo-controlled trials from undue harm?
- Eliminating all data monitoring
- Implementing independent Data Safety Monitoring Boards (DSMBs) and pre-specified stopping rules
- Refusing post-trial access to effective treatments
- Delaying adverse event reporting
Correct Answer: Implementing independent Data Safety Monitoring Boards (DSMBs) and pre-specified stopping rules
Q14. Post-trial access refers to what ethical obligation?
- Providing participants with financial compensation after publication
- Ensuring participants can access effective interventions identified in the trial after it ends when appropriate
- Publishing trial results in open access journals only
- Allowing unrestricted public use of trial data
Correct Answer: Ensuring participants can access effective interventions identified in the trial after it ends when appropriate
Q15. In an add-on placebo-controlled trial, placebo is given in which context?
- Participants receive no standard therapy and only placebo
- Placebo is added to standard therapy so all participants receive baseline effective treatment
- Placebo replaces standard therapy permanently
- Placebo is used only during follow-up after active drug
Correct Answer: Placebo is added to standard therapy so all participants receive baseline effective treatment
Q16. Why is equipoise considered a central ethical condition for enrolling patients into an RCT?
- It ensures patients receive equal monetary compensation
- It justifies random allocation because clinicians genuinely do not know which arm is superior
- It mandates the use of placebos in all trials
- It allows industry sponsors to decide treatment arms
Correct Answer: It justifies random allocation because clinicians genuinely do not know which arm is superior
Q17. Which statement best describes an ethical concern unique to cluster-randomized trials?
- Individual informed consent is always easier to obtain
- Interventions are randomized at group level, raising issues about who should provide consent and how to protect individual autonomy
- They never require ethics review
- They are exempt from reporting adverse events
Correct Answer: Interventions are randomized at group level, raising issues about who should provide consent and how to protect individual autonomy
Q18. Which approach reduces the ethical problem of withholding effective treatment while still allowing controlled comparison?
- Use of historical controls only
- Use of active-comparator or add-on trial designs rather than abandoning proven therapy for a placebo
- Using deception to mask treatment allocation
- Excluding participants with severe disease
Correct Answer: Use of active-comparator or add-on trial designs rather than abandoning proven therapy for a placebo
Q19. Which element is essential for assessing the risk–benefit balance of a placebo-controlled trial?
- Potential scientific value, magnitude of potential harm from placebo, availability of rescue therapy, and societal importance of knowledge
- Only the economic cost to the sponsor
- Number of investigators involved
- Whether the trial will be published
Correct Answer: Potential scientific value, magnitude of potential harm from placebo, availability of rescue therapy, and societal importance of knowledge
Q20. When reporting a clinical trial that used a placebo, which ethical reporting practice is required?
- Omitting details about placebo to protect proprietary methods
- Full transparency about placebo use, consent processes, justification for placebo, and harms observed
- Reporting only favorable outcomes
- Delaying adverse event disclosure until after product approval
Correct Answer: Full transparency about placebo use, consent processes, justification for placebo, and harms observed
